Ertugliflozin

艾托格列净

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameErtugliflozin
Drug Alias Nameertugliflozina埃格列净ertugliflozine厄格列净ertugliflozinum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Hypertension +[12] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2017/12/19
Country/TerritoryCanadaUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme BvStanford University +[6] 
Inactive CompaniesMedical University Of GrazPfizer IncUniversity Health Network (Uhn) +[4] 
Active IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Atherosclerosis +[6] 
Inactive IndicationsHypertensionHeart Failure, SystolicArrhythmias, Cardiac +[6] 

Other Information

ATC CodeA10BK04
Related LinksKEGG